Together, these findings emphasize that BET proteins orchestrate TAM phenotype, proliferation, and survival in a context- and protein-specific manner, and that selective targeting of BET proteins, particularly BRD4, along with rational combination strategies, may optimize TAM reprogramming and overcome resistance, highlighting the therapeutic potential of BET inhibitors in modulating the tumor microenvironment. This evidence concerns the gene DNER and neoplasm.